H
Healios
Biotech & Life Sciences · Tokyo, Japan · Founded 2011
Our mission is to foster a “Life Explosion” that enriches the lives of people around the world MoreLess
Healios K.K. is a pioneering biotechnology company specializing in regenerative medicine, focusing on the development and commercialization of treatments using induced pluripotent stem cells (iPSCs). The company serves a global market, targeting serious conditions such as ischemic stroke and age-related macular degeneration. Healios operates through strategic partnerships and licensing agreements with leading institutions like Nikon Corporation, Athersys, Inc., and RIKEN. The business model revolves around research and development, followed by licensing and commercialization of its proprietary cell therapy products. Revenue is generated through product sales, licensing fees, and milestone payments. Healios aims to bring cutting-edge medical solutions to market efficiently, leveraging its robust intellectual property portfolio and strategic alliances. Keywords: regenerative medicine, iPSC technology, cell therapy, ischemic stroke, macular degeneration, biotechnology, licensing agreements, strategic partnerships, commercialization, intellectual property.
Company overview
Healios company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2011
- Headquarters
- Tokyo, Japan
- Employees
- 32
- Open positions
- None listed
- Dealroom signal
- 79.3
- Investment activity
- 1 companies · latest Apr 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Healios funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPO✓Exit | Jun 2015 | $0 | — | Undisclosed | — |
| LATE VC✓Equity / VC | Oct 2013 | $23M | $92M | Dainippon Sumitomo Pharma · Shin Nippon Biomedical Laboratories (SNBL) · Nikon | — |
| EARLY VCEquity / VC | Oct 2012 | $210K | $840K | Nomura | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Healios website traffic
Latest recorded traffic for Healios is 22K monthly website visits, up 10% over the last three months. Healios's team grew 10.3% over the past year.
Comparisons
Healios compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Healios investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Healios's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Healios's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Healios has talent and traffic
team presence
In the news
Latest news about Healios
Recent press, funding announcements, and product moves mentioning Healios — open to read from the original sources.
Market sentiment
What the market is saying about Healios
An AI-synthesized read of the highest-engagement posts about Healios on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Healios’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.